Extended Data Fig. 2: Relative change from baseline in MRI-PDFF across time for TERN-501 monotherapy groups (Efficacy Analysis Set). | Nature Medicine

Extended Data Fig. 2: Relative change from baseline in MRI-PDFF across time for TERN-501 monotherapy groups (Efficacy Analysis Set).

From: TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

Extended Data Fig. 2

**P < 0.01; ***P < 0.001 for TERN-501 monotherapy versus placebo. Error bars represent standard error. Week 6: placebo (n = 21); TERN-501 1 mg (n = 23) P = 0.0088; TERN-501 3 mg (n = 22) P = 0.0006; TERN-501 6 mg (n = 20) P < 0.0001. Week 12: placebo (n = 21); TERN-501 1 mg (n = 23) P = 0.1303; TERN-501 3 mg (n = 19) P = 0.0036; TERN-501 6 mg (n = 18) P < 0.0001.Statistical analysis was performed using a type III sum of squares ANCOVA model with treatment group as a fixed effect and baseline value as the covariate; comparison between groups was conducted at the 2-sided, 0.05 level of significance, and no adjustments for multiplicity were made. LS, least squares; MRI-PDFF, magnetic resonance imaging proton density fat fraction.

Source data

Back to article page